Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities

Fares Qeadan, Nana A. Mensah, Lily Y. Gu, Erin F. Madden, Kamilla L. Venner and Kevin English
Additional contact information
Fares Qeadan: Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT 84108, USA
Nana A. Mensah: Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT 84108, USA
Lily Y. Gu: Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT 84108, USA
Erin F. Madden: Department of Family Medicine and Public Health Sciences, Wayne State University, Detroit, MI 48201, USA
Kamilla L. Venner: Department of Psychology, Center on Alcohol, Substance Use, and Addiction (CASAA), University of New Mexico, Albuquerque, NM 87131, USA
Kevin English: Albuquerque Area Southwest Tribal Epidemiology Center, Albuquerque, NM 87110, USA

IJERPH, 2021, vol. 18, issue 16, 1-16

Abstract: Background: Naltrexone, a medication for addiction treatment (MAT), is an FDA-approved medication recommended for the treatment of alcohol use disorder (AUD). Despite the high prevalence of AUD and efficacy of naltrexone, only a small percentage of individuals with AUD receive treatment. Objectives: To identify trends for the prescription of naltrexone in AUD admissions in substance use treatment centers across the U.S. Methods: Data from the 2000–2018 U.S. Treatment Episode Data Set: Admissions (TEDS-A) were used in temporal trend analysis of naltrexone prescription in admissions that only used alcohol. Data from the 2019 National Survey of Substance Abuse Treatment Services (N-SSATS) were also used to characterize medication use among AUD clients across different treatment service settings. Results: Treatment of AUD with naltrexone was 0.49% in 2000 and tripled from 0.53% in 2015 to 1.64% in 2018 in AUD admissions ( p < 0.0001 for the Cochran–Armitage trend test). Women, middle-aged adults, and admissions for clients living in the Northeast U.S. were more likely to be prescribed naltrexone than their respective counterparts, as were admissions with prior treatment episodes and referrals through alcohol/drug use care providers, who paid for treatment primarily through private insurance, used alcohol daily in the month prior to admission, and waited 1–7 days to enter treatment. Naltrexone was more commonly prescribed by AUD admissions compared to acamprosate and disulfiram and was more frequently prescribed in residential and outpatient services as opposed to hospital inpatient services. Conclusions: Naltrexone remains underutilized for AUD, and factors that influence prescription of medication are multifaceted. This study may contribute to the creation of effective interventions aimed at reducing naltrexone disparities for AUD.

Keywords: medication for addiction treatment; alcohol use disorder; TEDS-A; naltrexone (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/16/8884/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/16/8884/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:16:p:8884-:d:620221

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().